SILENCE THERAP. SP.ADR/1 (XRP2) — Net Asset Quality Index
SILENCE THERAP. SP.ADR/1 (XRP2) has a Net Asset Quality Index of 47.4% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €131.44 Million minus total liabilities of €69.14 Million yields net assets of €62.30 Million. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can SILENCE THERAP. SP.ADR/1 fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
SILENCE THERAP. SP.ADR/1 Net Asset Quality Index Over Time (2021–2025)
This chart shows how SILENCE THERAP. SP.ADR/1's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 47.4%, representing net assets of €62.30 Million against total assets of €131.44 Million EUR. Explore how efficiently does SILENCE THERAP. SP.ADR/1 generate cash to assess how effectively this company generates cash.
Annual Net Asset Quality Index for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for SILENCE THERAP. SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see XRP2 company net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 47.4% | €62.30 Million | €131.44 Million | €69.14 Million | ▼ -18.7 pp |
| 2024 | 66.1% | €134.02 Million | €202.63 Million | €68.61 Million | ▲ +47.7 pp |
| 2023 | 18.4% | €21.99 Million | €119.45 Million | €97.45 Million | ▼ -2.1 pp |
| 2022 | 20.5% | €26.71 Million | €130.10 Million | €103.38 Million | ▲ +11.7 pp |
| 2021 | 8.9% | €11.51 Million | €129.83 Million | €118.32 Million | — |